Clinical Trial Update: Comprehensive Characterization of Immune Response Induced by Adjuvanted Glycoprotein E (gE)-Based Recombinant VAccine Zoster in Vulnerable Population Receiving ImmunOmodulaNt Therapies

View source ↗

Summary

This clinical trial evaluates the immune response to Shingrix (glycoprotein E adjuvanted recombinant zoster vaccine) in vulnerable patients receiving immunomodu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• Shingrix (recombinant zoster vaccine, adjuvanted)

Snippet

Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia | Conditions: RZV Vaccine (Shingrix ®) | Status: RECRUITING